XNAS · ALLO
+1.30% · +$0.0200 · Vol Not reported
Pre-market · updated 05:26:07 ET
Allogene Therapeutics, Inc. Common Stock

Allogene Therapeutics, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$1.56
Card
Relationship Map

Follow $ALLO

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ALLO by email

Veridion Score

BETALOW CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
ALLO
Allogene Therapeutics, Inc. Common Stock
Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
Middle range · LOW confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5 of 6 factors measured · Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ALLO moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ALLO catalysts
About Allogene Therapeutics, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2018
Employees
152
Country
US

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.54
Last session
Day high
$1.54
Last session
Day low
$1.54
Last session
Previous close
$1.54
52W high
$3.06
-49.02% from high
52W low
$1.05
25% of range
Market cap
$532.1M
EPS
$-0.7800
Beta
1.23
Shares out
345.5M
Avg volume
5.5M
VWAP
$1.54
Last session
Price history computed in-house
1W
-5.45%
1M
-21.21%
3M
-25.00%
1Y
+20.93%
YTD
+13.87%
SMA 50 $1.88 · below
SMA 200 $1.99 · below
52W position 25%

ALLO overview

Veridion Score
59
Registered · 2026-10-01
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ALLO.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ALLO Form 4 filings
Public disclosures

Congress activity in ALLO

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ALLO in the cached public ledger.

Federal contracts

ALLO contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ALLO in this window.
Lobbying spend

ALLO lobbying filings, year to date.

Registered lobbying filings matched to Allogene Therapeutics, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ALLO in this window.
Loading news for ALLO
Analyst ratings
Sovereign unlock shows live analyst consensus for ALLO.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.